Related Experiment Video

Updated: Feb 2, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

The Role of Leukocytes in Diabetic Cardiomyopathy

Anamika Bajpai1, Douglas G Tilley1

  • 1Center for Translational Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States.

Frontiers in Physiology
|November 17, 2018
PubMed

Insights

Diabetes significantly increases cardiovascular disease risk. This review explores how leukocytes, like neutrophils and macrophages, contribute to diabetic heart failure, aiding new therapy development.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Endocrinology

Background:

  • Diabetes mellitus is a major risk factor for cardiovascular diseases, including myocardial infarction and heart failure.
  • Leukocytes, such as neutrophils, macrophages, and lymphocytes, are implicated in chronic inflammatory conditions like diabetes and heart failure.
  • The specific role of leukocytes in the pathogenesis of diabetic heart failure remains incompletely understood.

Purpose of the Study:

  • To review the current understanding of leukocyte involvement in the interplay between diabetes and heart failure.
  • To highlight the critical role of leukocytes in diabetic cardiomyopathy.
  • To identify potential therapeutic targets for diabetic heart failure based on leukocyte function.

Main Methods:

  • Literature review of studies investigating leukocytes in diabetes and heart failure.
  • Synthesis of findings on the individual and combined roles of neutrophils, macrophages, and lymphocytes.
  • Analysis of the inflammatory pathways linking diabetes, heart failure, and leukocyte activity.

Main Results:

  • Leukocytes play a significant role in the progression of both diabetes and heart failure independently.
  • Evidence suggests a complex interplay where leukocytes contribute to the pathogenesis of diabetic heart failure.
  • Specific leukocyte subsets and their inflammatory mediators are key players in diabetic cardiomyopathy.

Conclusions:

  • Understanding leukocyte function in diabetic heart failure is crucial for developing targeted therapies.
  • Modulating leukocyte activity presents a promising strategy for treating diabetic cardiomyopathy.
  • Further research into leukocyte-mediated inflammation can lead to novel therapeutic interventions for diabetic cardiovascular complications.

Keywords:
diabetesheart failureinflammationleukocytelymphocyte

More Related Videos

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature05:54

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature

Published on: January 24, 2025

722
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

649

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
568
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
490
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
538
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
442
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
605
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
356